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Abstract (249 words) 
 
Aim To determine the impact of emergent bradycardia and atrial fibrillation (AF) on 
cardiovascular outcomes in 19 083 patients with stable coronary artery disease (CAD) 
receiving ivabradine or placebo (SIGNIFY). 
Methods and Results Emergent bradycardia (resting heart rate <50 bpm on 12-lead 
electrocardiogram) with ivabradine was reported in 3572 patients (37.4%) overall, and 
in 2242 (37.2%) of patients with Canadian Cardiovascular Society (CCS) class ≥2 
angina. There was no difference in outcomes over the course of the study in 
ivabradine-treated patients with and without emergent bradycardia in the whole 
population (2.5% versus 2.9% per year, respectively, for primary composite endpoint 
of cardiovascular death or nonfatal myocardial infarction) or in the angina subgroup 
(2.5% versus 3.2% per year). Neither was there an increase in the rate of primary 
endpoint after emergent bradycardia was recorded compared with those without 
emergent bradycardia. There were 754 cases of emergent AF on treatment (2.2% per 
year ivabradine versus 1.5% per year placebo) and 469 in the patients with angina 
(2.2% versus 1.5% per year). While outcomes occurred more frequently in patients in 
whom emergent AF had been recorded, there was no treatment-placebo difference in 
outcomes, including stroke, and no difference in treatment effect in patients with 
limiting angina.  
Conclusion Both in the overall population as well as in the angina subset, bradycardia 
was common in ivabradine-treated patients, but did not appear to impact outcomes. 
Emergent AF was relatively rare and did not appear to have an impact on outcomes 
relative to placebo.   
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Introduction 
 
SIGNIFY (Study assessInG the morbidity–mortality beNefits of the If inhibitor 
ivabradine in patients with coronarY artery disease) analysed the effect of heart rate 
lowering with the If inhibitor ivabradine in patients with coronary artery disease 
(CAD) without clinical heart failure and with preserved left ventricular function.1 It 
was found that heart rate lowering with ivabradine did not improve outcomes, in 
particular the primary composite endpoint of cardiovascular death or nonfatal 
myocardial infarction, with an aggressive dosage regimen for ivabradine, starting at 
7.5 mg twice daily and uptitrating to 10 mg twice daily to achieve a heart rate of 55 to 
60 bpm. This regimen involved particularly high dosages of ivabradine, and neither 
the initiation nor the maintenance dosage employed in SIGNIFY is approved for 
ivabradine in clinical practice. Moreover, it was found that patients with limiting 
angina (Canadian Cardiovascular Society [CCS] class ≥2) appeared to fair less well in 
terms of outcomes with ivabradine compared with placebo. There was, however, 
evidence demonstrating symptomatic improvement with ivabradine in patients with 
angina.  
 
An explanation for these results has not been forthcoming. Among the most frequent 
cardiovascular adverse events were symptomatic and asymptomatic bradycardia, as 
well as atrial fibrillation. The purpose of the analysis described herein is to determine 
the role of bradycardia and atrial fibrillation in the SIGNIFY trial, and to explore 
whether they could account for the adverse finding in these patients. 
 
Methods 
 
Study design and patients 
 
The results and design of the SIGNIFY trial have been published in detail 
elsewhere.1,2 Briefly, this was a randomized, double-blind, event-driven, international 
trial. Ethical approval was obtained in all centres in the 51 participating countries and 
the trial was registered (ISRCTN61576291). To be eligible for inclusion, patients had 
to be aged 55 years or older with stable CAD, without clinical heart failure (left 
ventricular ejection fraction >40%). They also had to be in sinus rhythm with a resting 
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heart rate of 70 bpm or higher on two consecutive electrocardiography (ECG) 
readings. They had to have at least one major or two minor cardiovascular risk factors 
and be receiving appropriate standard background therapy. Patients with permanent 
atrial fibrillation or flutter were excluded from the trial. All patients provided written 
informed consent. 
 
After a 2- to 4-week placebo run-in, patients were randomly allocated to receive 7.5 
mg bid ivabradine or matched placebo (except for patients aged ≥75 years, who were 
initiated on 5 mg bid). Randomization was stratified according to centre and the 
presence of CCS class ≥2 angina at baseline. Dosages could be adjusted to 5.0, 7.5, or 
10 mg bid at every visit to achieve a resting heart rate between 55 and 60 bpm. The 
decision to modify the dosage of study treatment was made on the basis of ECG 
resting heart rate measurements at every visit, and symptoms of bradycardia.1,2 Study 
visits were scheduled at 1, 2, 3, and 6 months, and then every 6 months thereafter. All 
analyses described here are presented in the safety set, i.e. all patients who received at 
least one dose of study drug; this constituted 19 083 patients in the whole population 
and 12 039 patients with CCS class ≥2 angina at baseline. 
 
Analysis of emergent bradycardia 
 
We divided the SIGNIFY population according to the emergence of bradycardia, 
defined as resting heart rate <50 bpm on treatment, according to 12-lead ECG 
evaluation performed at every visit. In these routine evaluations, it was not formally 
recorded whether bradycardia was symptomatic or asymptomatic. The rates of 
bradycardia reported here differ from those reported in the main study,1 since they 
come from routine ECG evaluations and not from formal reports of adverse events by 
the investigator. Data relative to emergent bradycardia are presented as descriptive 
statistics only, since it was reported for too few patients in the placebo group for the 
purposes of comparison. Therefore, we report the rate of primary composite endpoint 
(cardiovascular death or non-fatal myocardial infarction) events with ivabradine and 
placebo over the course of the study, as well as after the occurrence of bradycardia in 
the whole population and in the prespecified subgroup of patients with CCS class ≥2 
angina at baseline.  
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Analysis of emergent atrial fibrillation 
 
We also divided the SIGNIFY population according to the occurrence of emergent 
atrial fibrillation on treatment. Diagnosis, signs, and symptoms of all adverse events 
related to rhythm and conduction disorders were reported by the investigator on the 
case report form, and this information was used to identify emergent atrial fibrillation.  
 
We analysed outcomes in patients with and without emergent atrial fibrillation for 
ivabradine versus placebo in the whole population and in the prespecified subgroup of 
patients with CCS class ≥2 angina at baseline. The outcomes analysed were the 
primary composite endpoint, and fatal or nonfatal stroke. For the outcomes analyses 
described here, only events that occurred after emergent atrial fibrillation were taken 
into account. If the outcome in question (notably myocardial infarction or stroke) 
occurred before the presentation of atrial fibrillation, then the patient was excluded 
from the outcomes analysis.  
 
Statistical methods 
 
The results for bradycardia are presented as descriptive statistics only. A Cox 
proportional hazards model was used to estimate the effect of treatment on outcomes 
in patients with and without emergent atrial fibrillation, and was adjusted for 
prognostic factors. Results are expressed in terms of hazard ratios and 95% 
confidence intervals (CIs). SAS software, version 9.2, was used for all statistical 
analyses. 
 
Results 
 
Our analyses covered 19 083 patients (9539 ivabradine, 9544 placebo) with a median 
follow-up of 27.8 months. There were 12 039 patients (6030 ivabradine, 6009 
placebo) in the subgroup with CCS class ≥2 angina. 
 
Bradycardia 
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Emergent bradycardia (resting heart rate <50 bpm on 12-lead ECG) with ivabradine 
was reported in 3572 patients in the whole population (37.4%) and 2242 patients in 
the subgroup with CCS class ≥2 angina (37.2%). The rates of emergent bradycardia in 
the placebo groups were 367 patients (3.8%) for the whole population and 261 
patients (4.3%) for the angina subgroup, respectively.  
 
In the whole population in whom emergent bradycardia was recorded on treatment 
with ivabradine, there were 211 patients (5.9%, 2.5% per year) who had a primary 
composite endpoint; this should be compared with 338 patients (5.8%, 2.9% per year) 
without emergent bradycardia. There were 132 (3.7%, 2.5% per year) who went on to 
have a primary composite endpoint after presenting with emergent bradycardia (Table 
1), of whom 12 patients (9%) had a primary composite endpoint within the month. In 
the group of patients with CCS class ≥2 angina with emergent bradycardia on 
treatment with ivabradine, there were 149 patients (6.7%, 2.8% per year) with a 
primary composite endpoint; this compares with 243 (6.6%, 3.2% per year) with a 
primary composite endpoint on treatment with ivabradine, but without emergent 
bradycardia. There were 86 patients (3.9%, 2.5% per year) who went on to have a 
primary composite endpoint after presenting with emergent bradycardia (Table 1), of 
whom 10 patients (12%) had the event within 1 month. Similar results were observed 
when bradycardia reported as an adverse event was taken into account (data not 
shown). 
 
Atrial fibrillation  
 
There were 754 cases of emergent atrial fibrillation on treatment (438 in the 
ivabradine group, 4.6% [2.2% per year], and 316 in the placebo group, 3.3% [1.5% 
per year]). Of the whole population in whom emergent atrial fibrillation was recorded 
on treatment with ivabradine, 14% (n=58, 10.9% per year) had a primary composite 
endpoint; this compares with 13.9% (n=42, 10.2% per year) in whom emergent atrial 
fibrillation was recorded on placebo. Table 2 shows events for the primary composite 
endpoint, and fatal or nonfatal stroke in patients after emergent atrial fibrillation 
compared with patients without emergent atrial fibrillation in the whole population. 
Fatal and nonfatal stroke occurred at rates of 4.6% and 4.2% in the ivabradine and 
placebo groups after emergent AF was recorded, respectively. 
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In the patients with CCS class ≥2 angina, there were 469 cases of emergent atrial 
fibrillation: 277 in the ivabradine patients (4.6% [2.2% per year]) and 192 in the 
placebo patients (3.2% [1.5% per year]). In these patients in whom emergent AF was 
recorded on treatment with ivabradine, there were 15.2% (n=40, 11.5% per year) who 
had a primary composite endpoint; this compares with 13.5% (n=25, 10.8% per year) 
in whom emergent AF was recorded on placebo. The results on outcomes in angina 
patients after emergent atrial fibrillation was recorded and those without emergent AF 
are presented in Table 2. The frequency of the primary composite endpoint and fatal 
and nonfatal stroke in this angina subgroup was greater following a recording of 
emergent atrial fibrillation in both treatment groups than in those who did not have 
emergent atrial fibrillation. However, there was no difference in the frequency of the 
primary composite endpoint in these patients with limiting angina according to the 
treatment they received and whether or not emergent atrial fibrillation occurred.  
 
Discussion 
 
A prespecified analysis of the BEAUTIFUL (morBidity-mortality EvAlUaTion of the 
If inhibitor ivabradine in patients with coronary disease and left-ventricULar 
dysfunction) study indicated that heart rate lowering with ivabradine in patients 
whose resting heart rate was ≥70 bpm was likely to be associated with a reduction in 
fatal and non-fatal myocardial infarction.3 The SIGNIFY study has demonstrated that 
this is not the case in patients without left ventricular dysfunction in whom heart rate 
lowering with ivabradine had no effect on the frequency of myocardial infarction.1 On 
the other hand, the SIGNIFY study did suggest that heart rate lowering with 
ivabradine was associated with an increase in the primary composite endpoint of 
cardiovascular death and non-fatal myocardial infarction in a prespecified subgroup of 
patients with CCS class ≥2 angina.1 
 
Whereas this conclusion appeared to be counterintuitive, we have explored the 
SIGNIFY database to try and obtain a better understanding of potential mechanisms 
that might explain these findings. Ivabradine has only a single mechanism of action 
on the heart, namely If current inhibition, which reduces heart rate, possibly leading to 
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bradycardia and the development of atrial fibrillation. It has no direct effects on blood 
pressure, coronary vascular resistance, or the myocardium.4  
 
In the SIGNIFY study, the frequency with which emergent bradycardia was recorded 
was much greater than previously described in patients treated with ivabradine,3 in 
spite of the higher heart rate at which treatment was initiated. This was to be expected 
because of the aggressive treatment regimen employed in SIGNIFY with titration of 
ivabradine to a heart rate of 55 to 60 bpm. Our results on emergent bradycardia do not 
suggest that heart rate <50 bpm on resting ECG is associated with an adverse outcome 
in terms of the primary composite endpoint. 
 
Our results in the placebo group indicate that 1.5% of patients with stable CAD and 
without clinical heart failure may expect to have an onset of atrial fibrillation within 1 
year. This is in line with epidemiological observations, which report an incidence of 
between 3 and 9 cases per 1000 person-years in the general population aged 65 years 
old.5 Registry data in patients with stable CAD suggest that between 2% and 19% 
have atrial fibrillation or flutter.6-10 Treatment with ivabradine appears to increase the 
absolute incidence of atrial fibrillation by 0.7% per year in stable CAD patients, 
including those with angina. The majority of cases of emergent atrial fibrillation with 
ivabradine in SIGNIFY were paroxysmal in nature and were managed according to 
current European guidelines.11,12 As would be expected,13 the outcome of SIGNIFY 
patients who developed atrial fibrillation was worse than in those without, 
independently of whether they were on ivabradine or placebo. On the other hand, the 
presence of atrial fibrillation did not affect the impact of treatment on incidence of 
primary composite endpoint or fatal or nonfatal stroke versus placebo. Indeed, our 
results do not suggest that atrial fibrillation was a substantial component of the 
apparent increase in the primary composite endpoint found in stable CAD patients 
with limiting angina.1 
 
The main limitation of our analysis is that we have created subgroups using post-
randomisation variables (emergent bradycardia or emergent atrial fibrillation). This 
means that, because the rate of occurrence of these events was different in the two 
treatment groups, then the usual subgroup interaction test cannot be interpreted in the 
usual manner. 
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In summary, neither the development of bradycardia nor the small increase in 
emergent atrial fibrillation appear to explain the increase in outcomes observed in the 
patients with CCS class ≥2 angina.  
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Table 1. Outcomes in patients with and without emergent bradycardia (resting heart 
rate <50 bpm on treatment, according to 12-lead ECG evaluation performed at every 
visit) in the whole population and in the population with Canadian Cardiovascular 
Society (CCS) class angina ≥2 at baseline. 
Patients with  primary composite endpoint (cardiovascular death or non-fatal myocardial infarction) 
events occurring before the emergence of bradycardia were excluded from the analysis. 
 
 Ivabradine  Placebo 
n Events, 
n (%) 
Events, 
% per 
year 
 n Events, 
n (%) 
Events,  
% per 
year 
Whole population (N=19 083) 
Primary composite endpoint  
• No emergent 
bradycardia 
5797 338 (5.8%) 2.9%  9032 487 (5.4%) 2.5% 
• Emergent bradycardia 3538 132 (3.7%) 2.5%  358 14 (3.9%) 3.1% 
Patients with CCS class ≥2 angina (N=12 039) 
Primary composite endpoint  
• No emergent 
bradycardia 
3678 243 (6.6%) 3.2%  5651 314 (5.6%) 2.6% 
• Emergent bradycardia 2215 86 (3.9%) 2.5%  255 10 (3.9%) 3.1% 
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Table 2. Outcomes in patients with and without emergent atrial fibrillation (AF) in 
the whole population and in the population with Canadian Cardiovascular Society 
(CCS) class angina ≥2 at baseline. 
Patients with primary composite endpoint (cardiovascular death or non-fatal myocardial infarction) and 
stroke events occurring before the emergence of atrial fibrillation were excluded from the analysis. 
 
 Ivabradine  Placebo  Hazard ratio (95% 
confidence interval) n Events, 
n (%) 
Events, 
% per 
year 
n Events, 
n (%) 
Events, 
% per 
year 
Whole population (N=19 083) 
Primary composite endpoint  
• No emergent AF 9101 572 (6.3%) 2.8%  9228 556 (6.0%) 2.7% 1.05 (0.94–1.18)  
• Emergent AF 414 58 (14.0%) 10.9%  303 42 (13.9%) 11.2% 1.02 (0.68–1.52)  
Fatal or nonfatal stroke  
• No emergent AF 9101 142 (1.6%) 0.7%  9228 138 (1.5%) 0.7% 1.06 ( 0.84–1.34)  
• Emergent AF 434 20 (4.6%) 3.5%  309 13 (4.2%) 3.2% 1.13 (0.55–2.30)  
Patients with CCS class ≥2 angina (N=12 039) 
Primary composite endpoint  
• No emergent AF 5753 406 (7.1%) 3.1%  5817 358 (6.2%) 2.7% 1.16 (1.01–1.34)  
• Emergent AF 264 40 (15.2%) 11.5%  185 25 (13.5%) 10.8% 1.14 (0.69–1.90)  
Fatal or nonfatal stroke  
• No emergent AF 5753 95 (1.7%) 0.7%  5817 89 (1.5%) 0.7% 1.10 (0.82–1.46) 
• Emergent AF 273 10 (3.7%) 2.7%  188 8 (4.3%) 3.2% 0.91 (0.35–2.37) 
 
